Cell & Gene Therapy Expertise

The science is stunningly complex, and the regulatory terrain is constantly evolving. Having supported over 90 cell and gene therapy trials in the past five years spanning oncology, hematology, metabolic disorders, and more, we know what it takes to succeed.

prcom_Asset 1ARROW

Exclusive Opportunity: Cell & Gene Therapy Consulting Session

Sign up for a free one-on-one discussion with Premier Research cell and gene therapy experts on Thursday, March 14th.

 

Supporting the evolving science of cell and gene therapy

Even measured against the vast scientific mystery that defines the biotech industry, cell and gene therapy poses extraordinary challenges. To achieve operational excellence in these trials, you must understand — and overcome — obstacles ranging from start-up regulations and site selection to patient recruitment and retention. And given the limited data on the long-term effects of these therapies, participants in cell and gene therapy trials may be monitored for a long-term follow-up period, which may be as long as 15 years.

For projects of this scale, you need a partner that can deliver from start to finish. That’s where Premier Research comes in.

We combine deep therapeutic expertise in oncology, rare disease, and pediatric research with other key areas, such as collaborative monitoring processes and technology. Together these allow us to deliver high-quality outcomes and an unwavering commitment to developers of next-generation therapies that makes us truly Built for Biotech℠.

Why choose Premier?
  • Over 90 cell and gene therapy studies conducted in the past five years
  • Significant experience in viral vectors
  • Significant experience in both oncology and non-oncology

Cell and Gene Therapy

Premier’s end-to-end capabilities in complex asset development transport breakthrough therapies through an evolving clinical and regulatory landscape to deliver novel treatments to patients in need. Get our brochure.

Managing long-term follow-up studies

To understand and mitigate the risk of delayed adverse events, participants in gene and cell therapy trials may be monitored for a long-term follow-up period. Learn what’s needed and how to determine if your product requires LTFU studies.

Featured Resources

Premier Insight

Premier Insight

#272: Delivering the Global Expertise Required to Coordinate a Pediatric Gene Therapy Trial

White Paper

White Paper

Operationalizing Gene Therapy Trials

Premier Insight

Premier Insight

#274: Site Selection, Manufacturing, & Long-Term Follow-Up in a Transition Phase 1/2 Gene Therapy Trial

Cell & Gene Therapy Experts

Olu Aloba, Ph.D.

Olu Aloba, Ph.D.

Vice President, CMC Services
Jessica Merryfield

Jessica Merryfield

Executive Director, Cell & Gene Therapy
Greg Meyer

Greg Meyer

Vice President, Regulatory Affairs
Kenneth Ndugga-Kabuye, MD, FACMG

Kenneth Ndugga-Kabuye, MD, FACMG

Vice President, Cell & Gene Therapy

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.